Clinical Research Directory

Inclusion Criteria: * Males or females, aged ≥65 years * Patients who received a renal allograft * Patients who are willing and able to participate in the study and from whom written informed consent has been obtained * Patients on an intended standard triple therapy with tacrolimus once daily (Advagraf with trough level ≥5ng/ml) in combination with mycophenolate (either ≥1.0g/day MMF or ≥720mg/d EC-MPS) and Steroids (≥5mg prednisolone or equivalent) * Patient must have received primary or secondary renal allograft from a blood group compatible donor (either deceased or living) * Patients with low to standard immunological risk, who had a PRA 20% (PRA testing according to center's practice) or no known donor specific antibodies at transplantation Exclusion Criteria: * Multi-organ recipients (solid organ or bone marrow) * More than secondary renal allograft recipients * Blood group A,B,O-incompatible allografts * Documented presence of donor specific antibodies (DSA) * Panel reactive antibody (PRA) \>20% prior to transplantation (PRA testing according to center's practice) * Patients having received any other induction therapy than Basiliximab or depleting polyclonal antithymocyte antibodies (ATG) (e.g. OKT3, Campath) * Patients receiving Sirolimus, Everolimus, Azathioprine, Belatacept or Cyclophosphamide within 3 months prior to or at enrolment * History of alcohol or drug abuse with less than 6 months of sobriety * Patient with any condition that may affect absorption of immunosuppressives, (e.g. severe diarrhoea, gastrectomy, active peptic ulcer disease or clinically significant diabetic gastroenteropathy) or tacrolimus metabolism (e.g. liver cirrhosis) * Patient with mental dysfunction or inability to cooperate within the study * Patients who have been institutionalized by official or court order